Bergen, 24 September 2018 - Myrlid AS, a company controlled by Kjetil Myrlid
Aasen, has today, purchased 129,800 subscription rights in PCI Biotech Holding
ASA's ("PCI Biotech") ongoing rights issue. The terms of the subscription rights
are described in PCI Biotech's prospectus dated 17 September 2018. As a result
of this transaction, Myrlid AS has increased its holding in PCI Biotech to
1,240,000 shares and 725,000 subscriptions rights, or from 4.96%, prior to the
initiation of the ongoing rights issue, to 7.86% of the current issued and
outstanding shares and votes in PCI Biotech (whereof 4.96% are shares and 2.90%
are subscription rights).
Aasen, including close associates, holds 1,720,000 shares and 993,800
subscription rights in PCI Biotech, equal to 10.86% ownership of the current
issued and outstanding shares and votes in PCI Biotech (whereof 6.88% are shares
and 3,98% are subscription rights).
This notification is based on the share capital of PCI Biotech being NOK
74,984,670 divided on 24,994,890 shares.